Pneumococcal conjugate vaccines: emerging clinical information and its implications (Q36600371)

15 August 2017

1 reference

title

Pneumococcal conjugate vaccines: emerging clinical information and its implications (English)

1 reference

15 August 2017

Stephen P Lockhart

1

1 reference

PubMed ID

16989635

15 August 2017

Jill G Hackell

series ordinal

2

1 reference

PubMed ID

16989635

15 August 2017

Bernard Fritzell

series ordinal

3

1 reference

15 August 2017

1 August 2006

1 reference

Expert Review of Vaccines

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

4

1 reference

15 August 2017

553-564

1 reference

The safety of 7-valent pneumococcal conjugate vaccine

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Infant immunization with pneumococcal CRM197 vaccines: effect of saccharide size on immunogenicity and interactions with simultaneously administered vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Dynamics of pneumococcal nasopharyngeal colonization during the first days of antibiotic treatment in pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Impact of a conjugate vaccine on community-wide carriage of nonsusceptible Streptococcus pneumoniae in Alaska

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Changes in frequency and pathogens causing acute otitis media in 1995-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.4.553

21 January 2018

Identifiers

DOI

10.1586/14760584.5.4.553

1 reference

15 August 2017

1 reference

PubMed ID

16989635